John Huemoeller, CEO of AXIM Biotechnologies, an international healthcare solutions company based in San Diego targeting oncological and COVID-19 research, discusses three first-of-their-kind COVID-19 neutralizing antibody tests. They have developed the world’s first rapid diagnostic test for detecting COVID-19 neutralizing antibodies and are waiting on EUA approval based on its proven test’s accuracy in blood and serum.

John Huemoeller currently serves as CEO of AXIM Biotechnologies, Inc. Mr. Huemoeller has over 35 years’ experience in investment banking, finance, sales and marketing. He began his career as an investment advisor in 1982 with M.L. Stern & Company a municipal bond firm in California and became a registered principal in 1985. He has previously been registered with various state insurance boards, as well as with the Chicago Board of Trade as a commodities broker. Mr. Huemoeller has worked for Smith Barney, Drexel Burnham, Prudential Securities, and Paine Webber and has extensive experience in stocks, bonds, commodities, mergers and acquisitions, leveraged buyouts and private placement transactions. Prior to becoming CEO of AXIM Biotechnologies, Inc. in 2018, Mr. Huemoeller served on the Board of Directors of AXIM Biotech, as Chairman of the Audit Committee, beginning in July 2017.